Publicly-traded company Haemonetics Corporation (NYSE:HAE) had a closing price of $120.73 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $146.17, this means that the stock is underpriced by 17.404%. In the past 52 weeks the company’s stock price has moved within the range of $80.24 to $140.36.
This particular stock’s 5-day moving average is 121.98, its 20-day moving average is 124.20 and its 100-day moving average is 124.83. Haemonetics Corporation (HAE) currently has 50770 shares outstanding, which means that its market capitalization is $6.13B.
The Details: Haemonetics Corporation (HAE) Financial Health
When thinking about a potential stock’s performance, there are a number of indicators that can help us understand the company’s financial health. Checking out a company’s current profit margin, for example, lets us know about how much of its total sales revenue was kept as earnings – which we find by taking net income and dividing it by total sales revenue. HAE currently has a profit margin of 5.10%.
Checking out a public company’s operating margin can also be helpful, as it shows us about how much profit is retained after the company factors out operating costs and depreciation. Haemonetics Corporation (HAE) has an operating margin of 6.70%.
We can also find the company’s Return on Assets, which is a percentage that shows us how well a company uses its current assets to make a profit. The larger the score, the better. At the moment, Haemonetics Corporation Return on Assets is 3.90%.
What Does Wall Street Say about Company?
When considering a stock buy, many investors seek to know what Wall Street analysts are saying about the company – by looking at the average analyst rating, for example. At the moment, the average analyst rating for HAE is Overweight. Out of 7 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 1 rated it an overweight, 2 rated it hold, and 4 rated it a Buy.
Understanding Profitability at Haemonetics Corporation (HAE)
A smart way of assessing a company’s profitability is by checking out its latest Earnings per Share (EPS). In the most recent financial results released by Haemonetics Corporation, for the quarter ending on 09/2019, the company posted EPS of 0.74. The average estimate of Wall Street analysts had projected 0.78.